Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aperture-collimated proton LATTICE radiotherapy with a GRID-like entrance pattern: a compact and robust delivery strategy.

Physics in medicine and biology·2026
Same author

Long-Term Changes in Physical Activity Among Cancer Survivors After Concurrent Chemoradiation Therapy: A Prospective Study.

International journal of radiation oncology, biology, physics·2026
Same author

Correction to: Systematic review of prophylactic antibacterial agents for radiation‑induced oral mucositis in head and neck cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Advancing Particle Therapy to Improve Cancer Care: Report on "2nd World Forum on Particle Therapy".

International journal of particle therapy·2026
Same author

A pig model of human radiation-induced veno-occlusive liver disease reveals ferroptosis as a therapeutic target.

Cell reports. Medicine·2026
Same author

TIP26-318: Protocol for Wearable AI Tracking to Curb Hospitalizations (WATCH).

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Mar 15, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Targeted Therapy for Hepatocellular Carcinoma.

Nitin Ohri1, Andreas Kaubisch2, Madhur Garg1

  • 1Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

Seminars in Radiation Oncology
|September 14, 2016
PubMed
Summary

Hepatocellular cancer (HCC) treatments are limited, necessitating new systemic options. This review explores emerging HCC drugs and radiotherapy combinations to improve patient outcomes.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.4K

Related Experiment Videos

Last Updated: Mar 15, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.4K

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Oncology drug development
  • Cancer therapy combinations

Background:

  • Hepatocellular cancer (HCC) is a major global cause of cancer mortality.
  • Most HCC patients are not candidates for curative local treatments.
  • Current systemic therapy (sorafenib) offers limited survival benefits for advanced HCC.

Purpose of the Study:

  • To review and categorize novel systemic drugs and targets for HCC treatment.
  • To explore the potential of combining new HCC agents with radiotherapy.
  • To guide future research for improved HCC patient outcomes.

Main Methods:

  • Literature review of drugs and targets in various phases of HCC testing.
  • Analysis of potential combination therapies with radiotherapy.
  • Identification of promising research directions.

Main Results:

  • Identification of multiple novel systemic agents and molecular targets for HCC.
  • Evaluation of synergistic potential between targeted therapies and radiotherapy.
  • Categorization of therapeutic strategies based on development phase.

Conclusions:

  • Novel systemic agents and combination therapies show promise for HCC.
  • Radiotherapy integration may enhance the efficacy of targeted HCC treatments.
  • Further research is essential to translate these findings into clinical practice.